Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2024.01.31
白熊生物：关于启动独立第三方调查的公告
2024.01.31
白熊生物：关于2023年度拟计提存货跌价准备的提示性公告
2024.01.31
白熊生物：2023年年度业绩预告
2024.01.16
白熊生物：关于收到深圳证监局监管关注函的公告
2024.01.15
白熊生物：关于子公司重要事项的公告
2024.01.10
白熊生物：2024年第一次临时股东大会决议公告
2023.12.19
白熊生物：关于联营公司君圣泰医药拟在香港联交所主板上市的公告
2023.12.18
白熊生物：关于召开2024年第一次临时股东大会的通知公告
2023.12.18
白熊生物：关于修订《公司章程》等相关制度的公告
2023.12.18
白熊生物：第六届董事会第六次会议决议公告
第一页
上一页
7
8
9
10
11
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
站点地图
